Programs that Stand up to Scrutiny
Our Scientific Advisory Board holds us to the highest standards of scientific practice.
View Advisory BoardRespiratory
Candidate
Targets
Partner
Our Commercial Rights
Discovery
Preclinical
Phase 1
Phase 2
Candidate
Elarekibep (PRS-060/AZD-1402)
Partner
Discovery complete
Preclinical complete
Phase 1 complete
Phase 2 in progress
Candidate
PRS-220
Discovery complete
Preclinical complete
Phase 1 in progress
Phase 2 not started
Candidate
PRS-400
Discovery in progress
Preclinical not started
Phase 1 not started
Phase 2 not started
Candidate
AstraZeneca Programs*
Partner
Discovery in progress
Preclinical not started
Phase 1 not started
Phase 2 not started
Candidate
Genentech Programs**
Partner
Discovery in progress
Preclinical not started
Phase 1 not started
Phase 2 not started
*3 additional respiratory programs in collaboration with AstraZeneca, 2 of which carry co-development and co-commercialization options for Pieris
**Collaboration includes 1 respiratory program and 1 ophthalmology program
Immuno-Oncology
Candidate
Targets
Partner
Our Commercial Rights
Discovery
Preclinical
Phase 1
Phase 2
Candidate
Cinrebafusp Alfa (PRS-343)*
Discovery complete
Preclinical complete
Phase 1 complete
Phase 2 in progress
Candidate
PRS-344/S095012
Partner
Discovery complete
Preclinical complete
Phase 1 in progress
Phase 2 not started
Candidate
PRS-346/SGEN-BB228
Partner
Discovery complete
Preclinical in progress
Phase 1 not started
Phase 2 not started
Candidate
PRS-342/BOS-342
Partner
Discovery complete
Preclinical in progress
Phase 1 not started
Phase 2 not started
Candidate
PRS-352
Partner
Discovery complete
Preclinical in progress
Phase 1 not started
Phase 2 not started
Candidate
Candidate Seagen Programs‡
Partner
Discovery complete
Preclinical in progress
Phase 1 not started
Phase 2 not started
‡ 3 bispecific programs (2 active; 1 forthcoming) in collaboration with Seagen.
*Company no longer enrolling the phase 2 study